Evaluation of a transdermal buprenorphine formulation in opioid detoxification

RK Lanier, A Umbricht, JA Harrison, ES Nuwayser… - …, 2007 - Wiley Online Library
Aims Buprenorphine is marketed in a sublingual formulation for treatment of opioid
dependence. A transdermal formulation has been developed that may provide extended …
被引用次数：26 相关文章

Evaluation of a transdermal buprenorphine formulation in opioid detoxification

RK Lanier, A Umbricht, JA Harrison… - Addiction …, 2007 - pubmed.ncbi.nlm.nih.gov
Aims Buprenorphine is marketed in a sublingual formulation for treatment of opioid
dependence. A transdermal formulation has been developed that may provide extended …

[引用][C] Evaluation of a transdermal buprenorphine formulation in opioid detoxification

RK LANIER, A UMBRICHT… - Addiction …, 2007 - pascal-francis.inist.fr
Evaluation of a transdermal buprenorphine formulation in opioid detoxification CNRS Inist
Pascal-Francis CNRS Pascal and Francis Bibliographic Databases Simple search Advanced …

Evaluation of a transdermal buprenorphine formulation in opioid detoxification.

RK Lanier, A Umbricht, JA Harrison… - Addiction (Abingdon …, 2007 - europepmc.org
Aims Buprenorphine is marketed in a sublingual formulation for treatment of opioid
dependence. A transdermal formulation has been developed that may provide extended …

Evaluation of a transdermal buprenorphine formulation in opioid detoxification

RK Lanier, A Umbricht, JA Harrison… - …, 2007 - pure.johnshopkins.edu
Aims: Buprenorphine is marketed in a sublingual formulation for treatment of opioid
dependence. A transdermal formulation has been developed that may provide extended …

[引用][C] Evaluation of a transdermal buprenorphine formulation in opioid detoxification

RK LANIER, A UMBRICHT, JA HARRISON… - Addiction, 2007 - Blackwell